1. Volume 6, Issue 6, Pages e382-e395 (June 2019)
Potential for additional government spending on HIV/AIDS in 137 low-income and middle-income countries: an economic modelling study 
Annie Haakenstad, MA, Mark W Moses, MHS, Tianchan Tao, BS, Golsum Tsakalos, MS, Bianca Zlavog, BS, Jennifer Kates, PhD, Adam Wexler, MPP, Christopher J L Murray, DPhil, Joseph L Dieleman, PhD 
The Lancet HIV 
Volume 6, Issue 6, Pages e382-e395 (June 2019)
DOI: /S (19)
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure 1
HIV/AIDS spending by financing source and spending category over time, 2000–16
All spending estimates are in 2018 US$.
The Lancet HIV 2019 6, e382-e395DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

3. Figure 2
Population living with HIV/AIDS and proportion of care and treatment spending financed by development assistance, 2016
The Lancet HIV 2019 6, e382-e395DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

4. Figure 3
HIV/AIDS care and treatment spending per year on ART (A) and prevention spending per prevalent HIV/AIDS case (B), 2016
All spending estimates are in 2018 US$. All high-income countries, as designated by the World Bank and Global Burden of Disease, were excluded (coloured in white). ART=antiretroviral therapy. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands. FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste.
The Lancet HIV 2019 6, e382-e395DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

5. Figure 4
Potential government spending on HIV/AIDS relative to existing development assistance and government HIV/AIDS spending, 2016
Data are from the 15 countries that received the most development assistance for health for HIV/AIDS in Observed HIV/AIDS care and treatment spending by development assistance and domestic spending compared with the potential for additional government spending (A), and as a percentage of observed total spending on HIV/AIDS care and treatment (B). We modelled the potential for additional government spending on HIV/AIDS relative to the current government health budget, public finance, health system, and HIV/AIDS contextual factors. All spending estimates are in 2018 US$.
The Lancet HIV 2019 6, e382-e395DOI: ( /S (19) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions